I Mab Stock Investor Sentiment

IMAB Stock  USD 0.98  0.05  5.38%   
About 55% of I Mab's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding I Mab suggests that some traders are interested. The current market sentiment, together with I Mab's historical and current headlines, can help investors time the market. In addition, many technical investors use I Mab stock news signals to limit their universe of possible portfolio assets.
  

I Mab Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards I Mab can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at Macroaxis         
Will Collegium (USA Stocks:COLL) shadow I Mab price surge?
Macroaxis News
over a month ago at businesswire.com         
BeiGene lamenta o falecimento do estimado membro do Conselho Donald Glazer
businesswire News
over a week ago at news.google.com         
Jennison Associates LLC Sells 110,333 Shares of Krystal Biotech, Inc. - MarketBeat
Google News at Macroaxis
over two weeks ago at gurufocus.com         
FMR LLCs Strategic Acquisition of Krystal Biotech Inc Shares
Gurufocus Stories at Macroaxis
over three weeks ago at thelincolnianonline.com         
Krystal Biotech Q2 EPS Forecast Increased by William Blair
news
over three weeks ago at zacks.com         
Krystal Biotech, Inc. Beats Q3 Earnings and Revenue Estimates
zacks News
over a week ago at www.macroaxis.com         
Disposition of 16692 shares by Salzmann Peter of Immunovant at 25.45 subject to Rule 16b-3
Macroaxis News
over two weeks ago at gurufocus.com         
FMR LLCs Strategic Acquisition of Immunovant Inc Shares
Gurufocus Stories at Macroaxis
over a month ago at investing.com         
Immunovant CEO Peter Salzmann sells 261,845 in shares
Investing News at Macroaxis
over three weeks ago at gurufocus.com         
Foghorn Therapeutics Inc Q3 2024 Earnings Revenue Surpasses Estimates at 7. ...
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Short Interest in Foghorn Therapeutics Inc. Increases By 9.1
news
over two months ago at finance.yahoo.com         
Foghorn Therapeutics to Participate in the BMO Oncology Summit
Yahoo News
over two months ago at investing.com         
Foghorn Therapeutics exec sells over 116k in company stock
Investing News at Macroaxis
over a week ago at news.google.com         
Citigroup Downgrades Shattuck Labs - MSN
Google News at Macroaxis
over three weeks ago at gurufocus.com         
Vanguard Group Incs Strategic Acquisition in Shattuck Labs Inc
Gurufocus Stories at Macroaxis
over a month ago at finance.yahoo.com         
Down -64.19 percent in 4 Weeks, Heres Why Shattuck Labs Looks Ripe for a Turnaround
Yahoo News
over a month ago at accesswire.com         
Shareholders that Lost Money on Shattuck Labs, Inc. Should Contact Levi Korsinsky About Securities F...
news
over two weeks ago at thelincolnianonline.com         
FY2028 Earnings Forecast for GLUE Issued By Wedbush
news
over three weeks ago at seekingalpha.com         
Monte Rosa Therapeutics GAAP EPS of -0.29
seekingalpha News
over a month ago at finance.yahoo.com         
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-mod...
Yahoo News
a day ago at zacks.com         
Wall Street Analysts See a 64.09 percent Upside in Monte Rosa Therapeutics Can the Stock Really Move...
zacks News
over two weeks ago at news.google.com         
Kymera Therapeutics Now Covered by Stephens - MarketBeat
Google News at Macroaxis
over three weeks ago at gurufocus.com         
Wellington Management Group LLPs Strategic Acquisition in Kymera Therapeutics Inc
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Kymera Therapeutics Releases Earnings Results, Beats Estimates By 0.01 EPS
news
over a month ago at finance.yahoo.com         
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a Fir...
Yahoo News
over three weeks ago at gurufocus.com         
Wellington Management Group LLP Increases Stake in Nurix Therapeutics Inc
Gurufocus Stories at Macroaxis
over a month ago at investing.com         
Nurix therapeutics chief scientific officer sells shares worth 83,536
Investing News at Macroaxis
over a month ago at globenewswire.com         
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert...
Macroaxis News: globenewswire.com
over two weeks ago at zacks.com         
Lyell Immunopharma Upgraded to Buy Heres What You Should Know
zacks News
over three weeks ago at globenewswire.com         
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 ...
Macroaxis News: globenewswire.com
over two months ago at news.google.com         
Lyell Immunopharma, Inc. Position Trimmed by Massachusetts Financial Services Co. MA - MarketBeat
Google News at Macroaxis
over a month ago at globenewswire.com         
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-97...
Macroaxis News: globenewswire.com
over three weeks ago at gurufocus.com         
Vanguard Group Incs Strategic Acquisition in Cullinan Therapeutics Inc
Gurufocus Stories at Macroaxis
over two months ago at news.google.com         
Cullinan Therapeutics Files Investigational New Drug Application with FDA for CLN-978 for Treatment ...
Google News at Macroaxis
over a year ago at news.google.com         
Theseus Pharmaceuticals Inc is lower by 3.62 percent Monday In Premarket Trading - InvestorsObserver
Google News at Macroaxis
few days ago at gurufocus.com         
Revolution Medicines to Host RAS Inhibitor Clinical Update Webcast on December 2, 2024
Gurufocus Stories at Macroaxis
over two weeks ago at investing.com         
Revolution Medicines executive sells shares worth 977,508
Investing News at Macroaxis
over three weeks ago at thelincolnianonline.com         
What is HC Wainwrights Estimate for RVMD Q3 Earnings?
news
over three weeks ago at finance.yahoo.com         
Revolution Medicines Inc Q3 2024 Earnings Report Preview What To Look For
Yahoo News
over three weeks ago at finance.yahoo.com         
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones ...
Yahoo News
over two weeks ago at news.google.com         
Technical Data - Stock Traders Daily
Google News at Macroaxis
over two weeks ago at zacks.com         
Erasca May Find a Bottom Soon, Heres Why You Should Buy the Stock Now
zacks News
over three weeks ago at news.google.com         
Erasca to Present at Three Major Healthcare Investor Conferences ERAS Stock News - StockTitan
Google News at Macroaxis
over a month ago at finance.yahoo.com         
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
Yahoo News
over two months ago at www.macroaxis.com         
Acquisition by Garner Ebun of 480000 shares of Erasca at 1.7 subject to Rule 16b-3
Macroaxis News
over two weeks ago at investing.com         
Citi cuts Ascendis Pharma stock target, maintains buy rating on volume growth
Investing News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Sivik Global Healthcare LLC Buys Shares of 10,000 Ascendis Pharma AS
news
over two months ago at finance.yahoo.com         
Ascendis Pharma AS Announces Proposed Public Offering of ADSs
Yahoo News
over two weeks ago at gurufocus.com         
Deep Track Capital, LP Reduces Stake in Dyne Therapeutics Inc
Gurufocus Stories at Macroaxis
over three weeks ago at thelincolnianonline.com         
Apellis Pharmaceuticals Given New 47.00 Price Target at Bank of America
news
over three weeks ago at globenewswire.com         
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Macroaxis News: globenewswire.com
over a month ago at finance.yahoo.com         
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 F...
Yahoo News
over a week ago at news.google.com         
Akero Therapeutics chief development officer sells 251,274 in stock - Investing.com
Google News at Macroaxis
over two weeks ago at gurufocus.com         
RTW INVESTMENTS, LP Expands Stake in Akero Therapeutics Inc
Gurufocus Stories at Macroaxis
over a month ago at www.macroaxis.com         
Disposition of 635 shares by Cheng Andrew of Akero Therapeutics at 21.1 subject to Rule 16b-3
Macroaxis News
over a week ago at news.google.com         
Disposition of 7500 shares by Coats Lonnel of Blueprint Medicines at 69.79 subject to Rule 16b-3
Google News at Macroaxis
over two weeks ago at thelincolnianonline.com         
HC Wainwright Reaffirms Buy Rating for Blueprint Medicines
news
over three weeks ago at finance.yahoo.com         
Disposition of 5000 shares by Albers Jeffrey W. of Blueprint Medicines at 36.05 subject to Rule 16b-...
Yahoo News
over a month ago at zacks.com         
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
zacks News
Far too much social signal, news, headlines, and media speculation about I Mab that are available to investors today. That information is available publicly through IMAB media outlets and privately through word of mouth or via IMAB internal channels. However, regardless of the origin, that massive amount of IMAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of I Mab news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of I Mab relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to I Mab's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive I Mab alpha.

I Mab Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
09/10/2024
2
I-Mabs Buy Rating Reiterated at HC Wainwright
09/20/2024
3
IMab Moves to Buy Rationale Behind the Upgrade
10/09/2024
4
I-Mab to Participate at the Truist Securities BioPharma Symposium - Morningstar
10/28/2024
5
I-Mab names Sean Fu as CEO
11/06/2024
6
I-Mab Reports Third Quarter 2024 Results
11/14/2024

Complementary Tools for IMAB Stock analysis

When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios